Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations

Key Findings

• ●Imatinib efficacy in SM lacking exon 17 KIT mutations
• ●Complete remission in 1 patient with K509I mutation

Referenced in (1 disease)

1. passsource metadataJun 1, 2026, 04:40 PMby pubmed-api

   Stored DOI was incorrect; corrected to the PubMed-registered DOI (verified to resolve to this article).

   tools: pubmed.esummary, crossref.works